Recombinant Human CCL26/Eotaxin‑3 (Catalog # 346‑E3) chemoattracts the BaF3 mouse pro‑B cell line transfected with mouse CCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to ...read more
Western blot shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 100 U/mL Recombinant Human IL‑4 (Catalog # 204-IL) for 24 hours. PVDF membrane was probed with 1 ...read more
E. coli-derived recombinant human CCL26/Eotaxin‑3 Thr24-Leu94 Accession # Q9Y258
Detects CCL26/Eotaxin‑3 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) Eotaxin, recombinant mouse (rm) Eotaxin, rhEotaxin-2, and rmEotaxin-2 is observed.
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for CCL26/Eotaxin-3 Antibody [Unconjugated]
CC chemokine IMAC
C-C motif chemokine 26
chemokine (C-C motif) ligand 26
Macrophage inflammatory protein 4-alpha
small inducible cytokine A26
small inducible cytokine subfamily A (Cys-Cys), member 26
Small-inducible cytokine A26
TSC-1Thymic stroma chemokine-1
Eotaxin-3, also named CCL26 or SCYA26, is a novel human CC chemokine that maps to chromosome 7q11.2, within 40 kilobases of the Eotaxin-2 loci. Eotaxin‑3/CCL26 has been shown to be constitutively expressed in the heart and ovary. In addition, low levels of Eotaxin-3/CCL26 expression can also be detected in various tissues. The expression of Eotaxin-3/CCL26 in vascular endothelial cells has been shown to be up-regulated by IL-13 and IL-4.
Eotaxin-3/CCL26 cDNA encodes a 94 amino acid (aa) residue protein with a putative signal peptide of either 23 or 26 aa residues. Recombinant Eotaxin-3/CCL26 has been produced in insect cells using a baculovirus expression system and shown to contain 71 aa residues. Recombinant Eotaxin-3/CCL26 is chemotactic for eosinophils and PHA-activated T cells. Eotaxin-3/CCL26 induces calcium flux in eosinophils as well as in CCR3-transfected cells. Eotaxin-3/CCL26 has also been shown to cross-desensitize cells to other CCR3 ligands. Both the 71 aa residue and 68 aa residue variants of recombinant Eotaxin-3 have been expressed in E. coli and found to have equal potency in inducing chemotaxis of a human CCR3-transfected cell line.
Gou, R.F. et al. (1999) Genomics 58:313.
Kitamura, M. et al. (1999) J. Biol. Chem. 274:27975.
Shinkai, A. et al. (1999) J. Immunol. 163:1602.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CCL26/Eotaxin-3 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.